Syncom Formulations (India) Ltd sees 7.15% stock price increase, outperforms sector by 6.59%

Syncom Formulations (India) Ltd, a smallcap pharmaceutical company, saw a 7.15% increase in its stock price on October 8th, 2024. The stock has been given a 'Hold' rating by MarketsMOJO, a leading financial analysis platform.

The stock's performance today has outperformed the sector by 6.59%, indicating a positive trend for the company. After three consecutive days of falling, the stock has shown a reversal and gained in value. It reached an intraday high of Rs 21.1, a 7.82% increase, and a low of Rs 18.99, a 2.96% decrease. The stock has been highly volatile today, with an intraday volatility of 5.5%.

Syncom Formulations (India) Ltd's moving averages are higher than the 50-day, 100-day, and 200-day moving averages, but lower than the 5-day and 20-day moving averages. This suggests a mixed trend for the stock in the short term.

In comparison to the Sensex, a benchmark index for the Indian stock market, Syncom Formulations (India) Ltd has shown a 1-day performance of 7.05% while the Sensex has only gained 0.47%. In the past month, the stock has underperformed the Sensex, with a -9.46% decrease compared to the Sensex's 0.31% increase.

Syncom Formulations (India) Ltd is a smallcap company in the pharmaceutical and drugs industry. It is a promising player in the market, with a positive trend in its stock performance. Investors should keep an eye on this company as it continues to grow and make its mark in the industry.